Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A
Top Cited Papers
Open Access
- 7 June 2001
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (23), 1735-1742
- https://doi.org/10.1056/nejm200106073442301
Abstract
We tested the safety of a nonviral somatic-cell gene-therapy system in patients with severe hemophilia A.Keywords
This publication has 19 references indexed in Scilit:
- What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?Haemophilia, 2001
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vectorNature Genetics, 2000
- Advances toward Gene Therapy for Hemophilia at the MillenniumHuman Gene Therapy, 1999
- Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 1996
- A new variant of Creutzfeldt-Jakob disease in the UKThe Lancet, 1996
- Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting‐factor concentrates considered safe against human immunodeficiency and hepatitis C virusesHaemophilia, 1995
- Review of the Hepatitis A Epidemics in Hemophiliacs in EuropeVox Sanguinis, 1994
- Prospective study of the evaluation of hepatitis C virus infectivity in a high‐purity, solvent/detergent‐treated factor VIII concentrate: parallel evaluation of other markers for lipid‐enveloped and non‐lipid‐ enveloped viruses.Transfusion, 1993
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992
- Regulation of Insulin-Gene ExpressionNew England Journal of Medicine, 1987